Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Chief Financial Officer | January 16, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date January 16, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2036-01-16 | Direct | 65,000 |
Reported balance
After 2026-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-16 · Grant · Acquired 65,000 · Balance 65,000 F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 100,000 |
Reported balance
After 2026-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-16 · Grant · Acquired 100,000 · Balance 100,000 F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.
F3: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.
F4: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 1,260 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · derivative · entry 14 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,740 Underlying: Common Stock · 1,260 shares Expires 2033-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F4 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 1,300 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · derivative · entry 13 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,700 Underlying: Common Stock · 1,300 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommno stock | 1,250 | $6.01 | $7,512.50 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 6 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 1,250 | $1.72 | $2,150.00 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 5 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 1,260 | $6.01 | $7,572.60 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 4 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 1,260 | $1.11 | $1,398.60 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 1,300 | $6.01 | $7,813.00 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 1,300 | $1.98 | $2,574.00 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 16:45 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 8,706 | $1.37 Strike: $1.37 | $11,927.22 |
DisclosureSEC source: 0001133416-25-000039 · form4.xml · derivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,706 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F3 · derivative.exercise_date: The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 16:45 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 8,706 | $6.44 | $56,053.58 |
DisclosureSEC source: 0001133416-25-000039 · form4.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $6.33 to $6.68. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 16:45 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 8,706 | $1.37 | $11,927.22 |
DisclosureSEC source: 0001133416-25-000039 · form4.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantRestricted Stock Unit · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-25-000004 · form4.xml · derivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-25-000004 · form4.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-01-23 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionRestricted Stock Units · Derivative | 40,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001133416-24-000068 · form4.xml · derivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024. F3 · derivative.exercise_price: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024. F3 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024. F3 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 40,000 | $0.89 | $35,492.00 |
DisclosureSEC source: 0001133416-24-000068 · form4.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F2 · shares: Shares of common stock sold pursuant to previously disclosed 10b5-1 plan. F4 · price: Multiple transactions ranging from $0.92 t0 $0.85 with an average price of $0.8873. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-24-000068 · form4.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock units. Read SEC document |
| January 24, 2024 Filed Feb 7, 2024 21:44 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantRestricted Stock Unit · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-24-000010 · form4.xml · derivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3 · derivative.exercise_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested. F3 · derivative.expiration_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested. Read SEC document |
| January 24, 2024 Filed Feb 7, 2024 21:44 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001133416-24-000010 · form4.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-01-24 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2024; December 31, 2024; June 30, 2025; and December 31, 2025. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:38 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-23-000016 · form4.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-26 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024. Read SEC document |
| November 17, 2022 Filed Nov 17, 2022 15:38 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 4,000 | $1.32 | $5,280.00 |
DisclosureSEC source: 0001133416-22-000101 · form4.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,614 Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 21:19 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-22-000018 · form4.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-24 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2022; December 31, 2022; June 30, 2023; and December 31, 2023. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013810 · doc4.xml · derivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F3 · derivative.exercise_date: Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013810 · doc4.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: Such options vest as follows: 25% on each on September 30, 2021, March 31, 2022, September 30, 2022 and March 31, 2023. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 22:58 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-20-001115 · doc4.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-09 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2020, December 31, 2020, June 30, 2021, and December 31, 2021. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:45 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock Purchase Warrant (right to buy) · Derivative | 7,847 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000037 · edgar.xml · derivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,847 Underlying: Common Stock · 585 shares Expires 2026-05-31 F1 · shares: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F1 · balance_after: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:45 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 2,354 | $4.28 | $10,075.12 |
DisclosureSEC source: 0001179022-19-000037 · edgar.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,614 Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 22:16 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001179022-19-000010 · edgar.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2019, December 31, 2019, June 30, 2020, and December 31, 2020. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 97,267 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001179022-18-000056 · edgar.xml · derivative · entry 8 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,267 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested as follows: (i) 12.5% on December 31, 2013, (ii) 25% on December 31, 2014, (iii) 25% on December 31, 2015, and (iv) 50% on December 31, 2016. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 97,267 | $8.08 | $786,034.08 |
DisclosureSEC source: 0001179022-18-000056 · edgar.xml · nonDerivative · entry 5 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 F4 · price: The shares were sold in multiple transactions at prices ranging from $8.0054 to $8.2592. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 97,267 | $4.41 | $428,947.47 |
DisclosureSEC source: 0001179022-18-000056 · edgar.xml · nonDerivative · entry 4 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 26,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001179022-18-000056 · edgar.xml · derivative · entry 7 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2025-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested as follows: 25% on January 29, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 102,733 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001179022-18-000056 · edgar.xml · derivative · entry 6 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,267 Underlying: Common Stock · 102,733 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested as follows: (i) 12.5% on December 31, 2013, (ii) 25% on December 31, 2014, (iii) 25% on December 31, 2015, and (iv) 50% on December 31, 2016. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 128,733 | $9.01 | $1,159,987.32 |
DisclosureSEC source: 0001179022-18-000056 · edgar.xml · nonDerivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 F3 · price: The shares were sold in multiple transactions at prices ranging from $9.00 to $9.0266. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 26,000 | $3.45 | $89,700.00 |
DisclosureSEC source: 0001179022-18-000056 · edgar.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 102,733 | $4.41 | $453,052.53 |
DisclosureSEC source: 0001179022-18-000056 · edgar.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:34 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 9,294 | $7.01 | $65,166.74 |
DisclosureSEC source: 0001179022-18-000052 · edgar.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:34 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 9,294 | $1.37 | $12,732.78 |
DisclosureSEC source: 0001179022-18-000052 · edgar.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 20:48 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001179022-18-000048 · edgar.xml · derivative · entry 6 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 20,000 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F3 · derivative.exercise_date: The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 20:48 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 20,000 | $6.38 | $127,500.00 |
DisclosureSEC source: 0001179022-18-000048 · edgar.xml · nonDerivative · entry 4 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F5 · price: The shares were sold in multiple transactions at prices ranging from $6.25 to $6.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 20:48 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 20,000 | $1.37 | $27,400.00 |
DisclosureSEC source: 0001179022-18-000048 · edgar.xml · nonDerivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Read SEC document |
| June 11, 2018 Filed Jun 14, 2018 20:34 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 9,294 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001179022-18-000052 · edgar.xml · derivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,706 Underlying: Common Stock · 9,294 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F2 · derivative.exercise_date: The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:48 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000048 · edgar.xml · derivative · entry 5 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F2 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:48 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 100,000 | $5.75 | $575,000.00 |
DisclosureSEC source: 0001179022-18-000048 · edgar.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F4 · price: The shares were sold in multiple transactions at prices ranging from $5.50 to $6.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:48 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 100,000 | $0.87 | $87,000.00 |
DisclosureSEC source: 0001179022-18-000048 · edgar.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:56 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 46,651 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000045 · edgar.xml · derivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 46,651 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F2 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:56 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 46,651 | $5.00 | $233,255.00 |
DisclosureSEC source: 0001179022-18-000045 · edgar.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:56 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 46,651 | $0.87 | $40,586.37 |
DisclosureSEC source: 0001179022-18-000045 · edgar.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001179022-18-000041 · edgar.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: The options vest as follows: 25% on June 30, 2018, 25% on September30, 2018, and 50% on December 31, 2018. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 3,349 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000025 · edgar.xml · derivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,651 Underlying: Common Stock · 3,349 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F2 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 3,349 | $5.00 | $16,745.00 |
DisclosureSEC source: 0001179022-18-000025 · edgar.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.